Vicore begins vital endothelial dysfunction study
The wide-ranging research aims to unlock the potential of angiotensin II type 2 receptor agonists
Read More
Tag: Vicore
Vicore Pharma bags MHRA nod for COVD-19 trial in record time
ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) is targeting hospitalised patients treated with basic respiratory care, but not mechanical ventilation
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
